A Viro-Immunotherapy Triple Play for the Treatment of Glioblastoma

John C Bell; Carolina S Ilkow

doi:10.1016/j.ccell.2017.07.012

A Viro-Immunotherapy Triple Play for the Treatment of Glioblastoma

Cancer Cell. 2017 Aug 14;32(2):133-134. doi: 10.1016/j.ccell.2017.07.012.

Authors

John C Bell¹, Carolina S Ilkow²

Affiliations

¹ Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada; Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, ON K1H 8L6, Canada. Electronic address: jbell@ohri.ca.
² Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada; Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, ON K1H 8L6, Canada.

PMID: 28810141
DOI: 10.1016/j.ccell.2017.07.012

Abstract

In this issue of Cancer Cell, Saha et al. systematically test and optimize combination therapy strategies in a challenging model of glioblastoma. Durable complete responses were seen only when an oncolytic virus expressing IL12 was coupled with anti-CTLA-4 and anti-PD-1 therapeutics.

Publication types

Comment

MeSH terms

Combined Modality Therapy
Glioblastoma*
Humans
Immunotherapy*
Oncolytic Virotherapy
Oncolytic Viruses